PF-04856264 is primarily utilized in the field of medical research, particularly in the study of neurological disorders. It acts as a selective inhibitor of the enzyme phosphodiesterase 10A (PDE10A), which is highly expressed in the brain and plays a role in regulating neuronal signaling. Researchers use this compound to investigate its potential therapeutic effects in conditions such as schizophrenia, Huntington's disease, and other psychiatric or neurodegenerative disorders. By modulating PDE10A activity, PF-04856264 helps scientists understand the underlying mechanisms of these diseases and explore new treatment strategies. Additionally, it is employed in preclinical studies to assess its efficacy, safety, and pharmacokinetic properties, contributing to the development of novel therapeutics.